Gastrointestinal stromal tumor (GIST) recurrence following surgery: review of the clinical utility of imatinib treatment

References

• HirotaSIsozakiKMoriyamaYGain-of-function mutations of c-kit in human gastrointestinal stromal tumorsScience199827953505775809438854
   PubMed Web of Science ®Google Scholar
• JoensuuHRobertsPSarlomo-RikalaMEffect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumorN Engl J Med2001344141052105611287975
   PubMed Web of Science ®Google Scholar
• PerezELivingstoneAFranceschiDCurrent incidence and outcomes of gastrointestinal mesenchymal tumors including gastrointestinal stromal tumorsJ Am Coll Surg2004202462362916571433
   PubMed Web of Science ®Google Scholar
• GoldJSDeMatteoRCombined surgical and molecular therapy: the gastrointestinal stromal tumor modelAnn Surg2006244217618416858179
   PubMed Web of Science ®Google Scholar
• MiettinenMLasotaJGastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosisArch Pathol Lab Med2006130101466147817090188
   PubMed Web of Science ®Google Scholar
• NikfarjamMKimchiEShereefSSurgical outcomes of patients with gastrointestinal stromal tumors in the era of targeted drug therapyJ Gastrointest Surg200812112023203118546049
   PubMed Web of Science ®Google Scholar
• DeMatteoRLewisJLeungDMudanSWoodruffJBrennanMTwo hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survivalAnn Surg20002311515810636102
   PubMed Web of Science ®Google Scholar
• HeinrichMCorlessCDuensingAPDGFRA activating mutations in gastrointestinal stromal tumorsScience2003299560770871012522257
   PubMed Web of Science ®Google Scholar
• RutkowskiPNoweckiZMichejWRisk criteria and prognostic factors for predicting recurrences after resection of primary gastrointestinal stromal tumorAnn Surg Oncol20071472018202717473953
   PubMed Web of Science ®Google Scholar
• NilssonBBümmingPMeis-KindblomJGastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era – a population-based study in western SwedenCancer2005103482182915648083
   PubMed Web of Science ®Google Scholar
• HeinrichMCorlessCDemetriGKinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumorJ Clin Oncol200321234342434914645423
   PubMed Web of Science ®Google Scholar
• Debiec-RychterMSciotRLe CesneAKIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumoursEur J Cancer20064281093110316624552
   PubMed Web of Science ®Google Scholar
• HeinrichMOwzarKCorlessCCorrelation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology GroupJ Clin Oncol200826335360536718955451
   PubMed Web of Science ®Google Scholar
• PierieJChoudryUMuzikanskyAYeapBSoubaWOttMThe effect of surgery and grade on outcome of gastrointestinal stromal tumorsArch Surg2001136438338911296107
   PubMedGoogle Scholar
• AparicioTBoigeVSabourinJPrognostic factors after surgery of primary resectable gastrointestinal stromal tumoursEur J Surg Oncol200430101098110315522557
   PubMed Web of Science ®Google Scholar
• DemetriGAntoniaSBenjaminRNCCN Clinical Practice Guidelines in Oncology, Soft Tissue Sarcoma2009
   Google Scholar
• VerweijJCasaliPZalcbergJProgression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trialLancet200436494401127113415451219
   PubMed Web of Science ®Google Scholar
• BlankeCRankinCDemetriGPhase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033J Clin Oncol200826462663218235122
   PubMed Web of Science ®Google Scholar
• DemetriGvan OosteromAGarrettCEfficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trialLancet200636895441329133817046465
   PubMed Web of Science ®Google Scholar
• GoldJvan der ZwanSGönenMOutcome of metastatic GIST in the era before tyrosine kinase inhibitorsAnn Surg Oncol200714113414217080234
   PubMed Web of Science ®Google Scholar
• DemetriGvon MehrenMBlankeCEfficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumorsN Engl J Med2002347747248012181401
   PubMed Web of Science ®Google Scholar
• VerweijJvan OosteromABlayJImatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II studyEur J Cancer200339142006201112957454
   PubMed Web of Science ®Google Scholar
• BlankeCDemetriGvon MehrenMLong-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KITJ Clin Oncol200826462062518235121
   PubMed Web of Science ®Google Scholar
• ZalcbergJVerweijJCasaliPOutcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mgEur J Cancer200541121751175716098458
   PubMed Web of Science ®Google Scholar
• DeMatteoRPAntonescuCRChadaramVAdjuvant imatinib mesylate in patients with primary high risk gastrointestinal stromal tumor (GIST) following complete resection: safety results from the U.S. intergroup phase II trial ACOSOG Z9000. [abstract]J Clin Oncol200523Suppl 16A-9009818s
   Web of Science ®Google Scholar
• DematteoRBallmanKAntonescuCAdjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trialLancet200937396691097110419303137
   PubMed Web of Science ®Google Scholar
• EisenbergBHarrisJBlankeCPhase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132/ACRIN 6665J Surg Oncol2009991424718942073
   PubMed Web of Science ®Google Scholar
• FioreMPalassiniEFumagalliEPreoperative imatinib mesylate for unresectable or locally advanced primary gastrointestinal stromal tumors (GIST)Eur J Surg Oncol200935773974519110398
   PubMed Web of Science ®Google Scholar
• ChoiHCharnsangavejCde Castro FariaSCT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: a quantitative analysis correlated with FDG PET findingsAJR Am J Roentgenol200418361619162815547201
   PubMed Web of Science ®Google Scholar
• ChoiHCharnsangavejCFariaSCorrelation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteriaJ Clin Oncol200725131753175917470865
   PubMed Web of Science ®Google Scholar
• RubinBFletcherJFletcherCMolecular insights into the histogenesis and pathogenesis of gastrointestinal stromal tumorsInt J Surg Pathol20008151011493959
   PubMed Web of Science ®Google Scholar
• de KogelCSchellensJHMImatinibOncologist200712121390139418165615
   PubMedGoogle Scholar
• FDAGleevec (imatinib mesylate) Revised Product Label2006
   Google Scholar
• van OosteromAJudsonIVerweijJSafety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I studyLancet200135892911421142311705489
   PubMed Web of Science ®Google Scholar
• TonyaliOCoskunUYildizRImatinib mesylate-induced acute liver failure in a patient with gastrointestinal stromal tumorsMed Oncol200987 Epub ahead of print
   Web of Science ®Google Scholar
• Van GlabbekeMVerweijJCasaliPPredicting toxicities for patients with advanced gastrointestinal stromal tumours treated with imatinib: a study of the European Organisation for Research and Treatment of Cancer, the Italian Sarcoma Group, and the Australasian Gastro-Intestinal Trials Group (EORTC-ISG-AGITG)Eur J Cancer200642142277228516876399
   PubMed Web of Science ®Google Scholar
• JiangYMingLMonteroAKimchiENikfarjamMStaveley-O’CarrollKOptimizing imatinib mesylate treatment in gastrointestinal stromal tumorsGastrointest Cancer Res20082524525019259308
   PubMedGoogle Scholar
• DemetriGCasaliPBlayJA phase I study of single-agent nilotinib or in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumorsClin Cancer Res200915185910591619723647
   PubMed Web of Science ®Google Scholar
• HuynhHLeeJChowPSorafenib induces growth suppression in mouse models of gastrointestinal stromal tumorMol Cancer Ther20098115215919139124
   PubMed Web of Science ®Google Scholar
• GuoTAgaramNWongGSorafenib inhibits the imatinib-resistant KITT670I gatekeeper mutation in gastrointestinal stromal tumorClin Cancer Res200713164874488117699867
   PubMed Web of Science ®Google Scholar
• RautCPosnerMDesaiJSurgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitorsJ Clin Oncol200624152325233116710031
   PubMed Web of Science ®Google Scholar
• DeMatteoRMakiRSingerSGonenMBrennanMAntonescuCRResults of tyrosine kinase inhibitor therapy followed by surgical resection for metastatic gastrointestinal stromal tumorAnn Surg2007245334735217435539
   PubMed Web of Science ®Google Scholar
• GronchiAFioreMMiselliFSurgery of residual disease following molecular-targeted therapy with imatinib mesylate in advanced/metastatic GISTAnn Surg2007245334134617435538
   PubMed Web of Science ®Google Scholar